PŘEHLEDOVÉ ČLÁNKY Album-in & Album-out – pohled za oponu nových doporučení E14 | VNITŘNÍ LÉKAŘSTVÍ / Vnitř Lék. 2024;70(8):E11-E14 / www.casopisvnitrnilekarstvi.cz LITERATURA 1. Peters T Jr. All about albumin: Biochemistry, genetics and medical applications. Academic Press; 2014. ISBN 9780080527048. 2. Callum J, Skubas NJ, Bathla A, et al. Use of intravenous albumin. Chest. 2024;166(2):32138. Available from DOI: 10.1016/j.chest.2024. 02. 049. 3. Weinbaum S, Tarbell JM, Damiano ER. The structure and function of the endothelial glycocalyx layer. Annu Rev Biomed Eng. 2007;9(1):121-67. Available from 10.1146/annurev. bioeng.9.060906.151959. 4. Woodcock TE, Woodcock TM. Revised Starling equation and the glycocalyx model of transvascular fluid exchange: an improved paradigm for prescribing intravenous fluid therapy. Br J Anaesth. 2012;108(3):384-94. Available from DOI: 10.1093/bja/aer515. 5. Uchimido R, Schmidt EP, Shapiro NI. The glycocalyx: a novel diagnostic and therapeutic target in sepsis. Crit Care. 2019;23(1). Available from DOI: 10.1186/s13054-018-2292-6. 6. Evans L, Rhodes A, Alhazzani W et al. Surviving sepsis campaign: International guidelines for management of sepsis and septic shock 2021. Crit Care Med. 2021;49(11):e1063143. Available from DOI: 10.1097/ccm.0000000000005337. 7. The SAFE Stud Investigators: A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med. 2004;350(22):2247–56. Available from DOI: 10.1056/nejmoa040232. 8. Caironi P, Tognoni G, Masson S, et al. Albumin replacement in patients with severe sepsis or septic shock. N Engl J Med. 2014;370(15):1412–21. Available from DOI: 10.1056/ nejmoa1305727 9. Park C, Osawa E, Almeida J, et al. Lactated Ringer Versus Albumin in Early Sepsis Therapy (RASP) study: preliminary data of a randomized controlled trial. Crit Care. 2015;19(S1). Available from DOI: 10.1186/cc14435 10. Tseng C-H, Chen T-T, Wu M-Y, et al. Resuscitation fluid types in sepsis, surgical, and trauma patients: a systematic review and sequential network meta-analyses. Crit Care. 2020;24(1). Available from DOI: 10.1186/s13054-020-03419-y 11. Patel A, Laffan MA, Waheed U, et al. Randomised trials of human albumin for adults with sepsis: systematic review and meta-analysis with trial sequential analysis of all-cause mortality. BMJ. 2014;349(jul22 10):g4561–g4561. Available from DOI: 10.1136/bmj.g4561 12. Lewis SR, Pritchard MW, Evans DJW, et al. Colloids versus crystalloids for fluid resuscitation in critically ill people. Cochrane Libr. 2018; Available from DOI: 10.1002/14651858. cd000567.pub7. 13. Moramarco S, Morciano L, Morucci L, et al. Epidemiology of hypoalbuminemia in hospitalized patients: A clinical matter or an emerging public health problem? Nutrients. 2020;12(12):3656. Available from DOI: 10.3390/nu12123656. 14. Dubois M-J, Orellana-Jimenez C, Melot C, et al. Albumin administration improves organ function in critically ill hypoalbuminemic patients: A prospective, randomized, controlled, pilot study. Crit Care Med. 2006;34(10):2536-40. Available from DOI: 10.1097/01. ccm.0000239119.57544.0c. 15. Burke E, Datar SA. Lymphatic dysfunction in critical illness. Curr Opin Pediatr. 2018;30(3):332–7. Available from DOI: 10.1097/mop.0000000000000623. 16. Olsen H, Andersen A, Nordbø A, et al. Pharmaceutical-grade albumin: impaired drug- -binding capacity in vitro. BMC Clin Pharmacol. 2004;4(1). Available from DOI: 10.1186/14726904-4-4. 17. Gatz R, Elbers P. Albumin is not a buffer in plasma. Blood Transfus. 2011;9(1). Available from https://pubmed.ncbi.nlm.nih.gov/21084018/ 18. Caraceni P, Riggio O, Angeli P, et al. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. Lancet. 2018;391(10138):2417–29. Available from DOI: 10.1016/s0140-6736(18)30840-7. 19. Solà E, Solé C, Simón-Talero M, et al. Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial. J Hepatol. 2018;69(6):1250-9. Available from DOI: 10.1016/s00165085(96)70068-9 20. China L, Freemantle N, Forrest E, et al. A randomized trial of albumin infusions in hospitalized patients with cirrhosis. N Engl J Med. 2021;384(9):808-17. Available from DOI: 10.1056/nejmoa2022166 21. Maiwall R, Kumar A, Pasupuleti SSR, et al. A randomized-controlled trial comparing 20% albumin to plasmalyte in patients with cirrhosis and sepsis-induced hypotension [ALPS trial]. J Hepatol. 2022;77(3):670-82. Available from DOI: 10.1016/j.jhep.2022. 03. 043 22. Arabi YM, Belley-Cote E, Carsetti A, et al. European Society of Intensive Care Medicine clinical practice guideline on fluid therapy in adult critically ill patients. Part 1: the choice of resuscitation fluids. Intensive Care Med. 2024;50(6):813-31. Available from DOI: 10.1007/ s00134-024-07369-9 23. Ginès P, Titó L, Arroyo V et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology. 1988;94(6):1493502. Available from DOI: 10.1016/0016-5085(88)90691-9 24. Bernardi M, Caraceni P, Navickis RJ et al. Albumin infusion in patients undergoing large-volume paracentesis: A meta-analysis of randomized trials. Hepatology. 2012;55(4):117281. Available from DOI: 10.1002/hep.24786 25. Simonetti RG, Perricone G, Nikolova D, et al. Plasma expanders for people with cirrhosis and large ascites treated with abdominal paracentesis. Cochrane Libr. 2019; Available from DOI: 10.1002/14651858.cd004039.pub2 26. Alessandria C, Elia C, Mezzabotta L, et al. Prevention of paracentesis-induced circulatory dysfunction in cirrhosis: Standard vs half albumin doses. A prospective, randomized, unblinded pilot study. Dig Liver Dis. 2011; Available from DOI: 10.1016/j.dld.2011. 06. 001 27. Sanyal AJ, Boyer T, Garcia-Tsao G, et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology. 2008;134(5):1360-8. Available from DOI: 10.1053/j.gastro.2008. 02. 014. 28. Solanki P, Chawla A, Garg R, et al. Beneficial effects of terlipressin in hepatorenal syndrome: A prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol. 2003;18(2):152-6. Available from DOI: 10.1046/j.1440-1746.2003.02934.x. 29. Sagi SV, Mittal S, Kasturi KS, et al. Terlipressin therapy for reversal of type 1 hepatorenal syndrome: A meta-analysis of randomized controlled trials. J Gastroenterol Hepatol. 2010;25(5):880-5. Available from DOI: 10.1111/j.1440-1746.2009.06132.x. 30. Ortega R, Ginès P, Uriz J, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: Results of a prospective, nonrandomized study: Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: Results of a prospective, nonrandomized study. Hepatology. 2002;36(4):941-8. Available from DOI: 10.1053/jhep.2002.35819. 31. Best LMJ, Freeman SC, Sutton AJ, et al. Treatment for hepatorenal syndrome in people with decompensated liver cirrhosis: a network meta-analysis. Cochrane Libr. 2019;2019(11). Available from DOI: 10.1002/14651858.cd013103.pub2. 32. Thomson MJ, Taylor A, Sharma P. Limited progress in hepatorenal syndrome (HRS) reversal and survival 2002–2018: A systematic review and meta-analysis. Dig Dis Sci. 2020;65(5):1539-48. Available from DOI: 10.1007/s10620-019-05858-2. 33. Fernández J, Angeli P, Trebicka J et al. Efficacy of albumin treatment for patients with cirrhosis and infections unrelated to spontaneous bacterial peritonitis. Clin Gastroenterol Hepatol. 2020;18(4):963-973.e14. Available from DOI: 10.1016/j.cgh.2019. 07. 055. 34. Sort P, Navasa M, Arroyo V et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med. 1999;341(6):403-9. Available from DOI: 10.1056/nejm199908053410603 35. Thévenot T, Christophe Bureau, Oberti F et al. Effect of albumin in cirrhotic patients with infection other than spontaneous bacterial peritonitis. A randomized trial. J Hepatol. 2015;62(4):822-30. Available from DOI: 10.1016/j.jhep.2014. 11. 017. 36. Kitsios GD, Mascari P, Ettunsi R, et al. Co-administration of furosemide with albumin for overcoming diuretic resistance in patients with hypoalbuminemia: A meta-analysis. J Crit Care. 2014;29(2):253-9. Available from DOI: 10.1016/j.jcrc.2013. 10. 004. 37. Knoll GA, Grabowski JA, Dervin GF, et al. A randomized, controlled trial of albumin versus saline for the treatment of intradialytic hypotension. J Am Soc Nephrol. 2004;15(2):48792. Available from DOI: 10.1097/01.asn.0000108971.98071.f2. 38. Rostoker G, Griuncelli M, Loridon C et al. A pilot study of routine colloid infusion in hypotension-prone dialysis patients unresponsive to preventive measures. J Nephrol. 2011;24(2):208-17. Available from DOI: 10.5301/jn.2011.6367. 39. Van Der Sande FM, Kooman JP, Barendregt JNM, et al. Effect of intravenous saline, albumin, or hydroxyethylstarch on blood volume during combined ultrafiltration and hemodialysis. J Am Soc Nephrol. 1999;10(6):1303–8. Available from DOI: 10.1681/asn.v1061303. 40. Macedo E, Karl B, Lee E, et al. A randomized trial of albumin infusion to prevent intradialytic hypotension in hospitalized hypoalbuminemic patients. Crit Care. 2021;25(1). Available from DOI: 10.1186/s13054-020-03441-0.
RkJQdWJsaXNoZXIy NDA4Mjc=